Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Lloyd Clark, Kiaweh Eye 2021: Diabetic Retinopathy and Diabetic Macular Oedema – Trends in Transitioning Treatment

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 21st 2021

Lloyd Clark (Palmetto Retina Center, West Columbia, SC, USA) shared with us his views on unresolved challenges in the treatment of diabetic retinopathy and diabetic macular oedema.

Questions

  1. What are the unresolved challenges in the treatment of diabetic retinopathy and diabetic macular oedema? (00:22)
  2. How are dosing strategies evolving to maintain initial visual acuity gains, while extending the time between dosing intervals? (01:35)

Speaker Disclosure: Lloyd Clark discloses the following: Consultant for Bayer, Genentech/Roche, Regeneron Pharmaceuticals; honoraria from  Genentech/Roche, Regeneron Pharmaceuticals; grant support from Bayer, Genentech/Roche, Kodiak Pharmaceuticals, Regeneron Pharmaceuticals.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of Kiaweh Eye 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup